• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Venus Concept Appoints Ross J. Portaro as President of Global Sales

    10/12/21 7:30:00 AM ET
    $VERO
    Medical/Dental Instruments
    Health Care
    Get the next $VERO alert in real time by email

    TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022.

    "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Medical, Lumenis, Medicis Pharmaceutical, TRIA Beauty and Ulthera, Inc." said Domenic Serafino, Chief Executive Officer and Director of Venus Concept Inc. "He has made important contributions to the success of our organization as our Vice President of EMEA, and I am pleased to announce his promotion to the position of President of Global Sales. With Ross as a member of our senior leadership team, I believe Venus Concept is well positioned to continue building a world class sales organization committed to integrity and exceptional customer satisfaction. I would also like to thank Chad for his hard work and contributions. We wish him well in his future endeavours."

    "Venus Concept is a true innovator in the field of aesthetic technology," said Mr. Portaro. "I was attracted to the Company because of its unique product offerings and development of new robotic technologies, and I am excited by the opportunity to play a key role in its next phase of growth and development as an organization."

    Mr. Portaro joined Venus Concept as Vice President of EMEA in May, 2021, responsible for developing the sales strategy and managing all sales and utilization activity via direct and distribution sales channels in the region. Prior to joining Venus Concept, he worked for Candela Medical, a global medical aesthetic device company, from 2016 until 2021 in a series of positions, including Vice President of EMEA Direct and Global Vice President of Candela's Surgical Aesthetic Business Unit. Mr. Portaro previously served as Senior Vice President of Sales for BioPharmX, Inc. from 2014 to 2016. His career experience also includes positions at Medicis Pharmaceutical (2010 to 2013), TRIA Beauty (2006 to 2009) and Lumenis (2004 to 2006). Mr. Portaro holds a B.S. in Commerce from the University of Virginia's McIntyre School of Commerce.

    About Venus Concept

    Venus Concept is an innovative global medical aesthetic technology leader with a broad product portfolio of minimally invasive and non-invasive medical aesthetic and hair restoration technologies and reach in over 60 countries and 19 direct markets. Venus Concept focuses its product sales strategy on a subscription-based business model in North America and in its well-established direct global markets. Venus Concept's product portfolio consists of aesthetic device platforms, including Venus Versa, Venus Legacy, Venus Velocity, Venus Fiore, Venus Viva, Venus Freeze Plus, Venus Glow, Venus Bliss, Venus Epileve and Venus Viva MD. Venus Concept's hair restoration systems include NeoGraft®, an automated hair restoration system that facilitates the harvesting of follicles during a FUE process and the ARTAS® and ARTAS iX® Robotic Hair Restoration systems, which harvest follicular units directly from the scalp and create recipient implant sites using proprietary algorithms. Venus Concept has been backed by leading healthcare industry growth equity investors including EW Healthcare Partners (formerly Essex Woodlands), HealthQuest Capital, Longitude Capital Management, and Aperture Venture Partners.



    Investor Relations Contact:
    
    Westwicke Partners on behalf of Venus Concept:
    
    Mike Piccinino, CFA
    
    [email protected]

    Primary Logo

    Get the next $VERO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VERO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $VERO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Venus Concept Announces Up To $3.45 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

      TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced that it has entered into definitive agreements for the purchase and sale of 434,720 shares of common stock at a purchase price of $2.65 per share in a registered direct offering priced at-the-market under Nasdaq rules. In a concurrent private placement, the Company will issue unregistered short-term warrants to purchase up to 869,440 shares of common stock at an exercise price of $2.65 per share that will be immediately exercisable upon issuance and will expire eighteen months following the effective date of the regist

      6/6/25 11:35:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces Definitive Agreement to Sell Venus Hair Business for $20 Million

      TORONTO, June 06, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today it has entered into a definitive agreement to sell its Venus Hair business to MHG Co. Ltd ("Meta Healthcare Group") in an all-cash transaction valued at $20 million, subject to a customary working capital adjustment. The net proceeds from the transaction, once completed, will enhance the Company's balance sheet and financial condition and provide valuable capital to fund strategic growth initiatives. "We are pleased to announce one outcome of our evaluation of strategic alternatives to maximize shareholder value," sai

      6/6/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Announces First Quarter 2025 Financial Results

      TORONTO, May 15, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced financial results for the three months ended March 31, 2025. Summary of Financial Results & Recent Progress: Total revenue for the first quarter of $13.6 million, down 22% year-over-year, reflecting continued difficult market conditions. First quarter operating expenses declined 6% year-over-yearFirst quarter GAAP net loss of $12.4 million, compared to $9.8 million last yearFirst quarter Adjusted EBITDA loss of $8.3 million, compared to $5.1 million last year On April 1, 2025, the Company exchanged $11.0 million of its sub

      5/15/25 7:00:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Large owner Madryn Asset Management, Lp

      4 - Venus Concept Inc. (0001409269) (Issuer)

      4/2/25 5:47:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Director Natale Anthony sold $13,194 worth of shares (42,768 units at $0.31) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      12/4/24 5:43:14 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Large owner Masters Michael Willingham sold $179,641 worth of shares (306,135 units at $0.59) (SEC Form 4)

      4 - Venus Concept Inc. (0001409269) (Issuer)

      10/2/24 7:54:31 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Leadership Updates

    Live Leadership Updates

    See more
    • Venus Concept Inc. Appoints Dr. Hemanth Varghese as President and Chief Operating Officer and Industry Veteran to Lead International Operations

      TORONTO, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the promotion of Dr. Hemanth Varghese to the newly created role of President and Chief Operating Officer (COO), reporting to Chief Executive Officer, Rajiv De Silva, effective October 16, 2023. Dr. Varghese joined Venus Concept in October of 2022 as President and Chief Business Officer. His responsibilities were later expanded to include the Chief Innovation Officer role as well. Dr. Varghese has been pivotal in developing and executing the Company's turnaround strategy. In his new role, Dr. Varghese will assume

      10/12/23 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Dr. Hemanth Varghese as President & Chief Business Officer

      TORONTO, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Dr. Hemanth Varghese to the position of President & Chief Business Officer, effective October 17, 2022. "We are delighted to have Hemanth join Venus Concept at this pivotal time for the Company," said Rajiv De Silva, Chief Executive Officer and Director of Venus Concept. "Hemanth is an accomplished healthcare executive with a 20-year track record of performance and execution. He is a versatile leader with experience leading diverse healthcare businesses in high-growth markets in North America and in

      10/11/22 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Appoints Ross J. Portaro as President of Global Sales

      TORONTO, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, today announced the appointment of Ross J. Portaro to the position of President of Global Sales, effective October 15, 2021. Mr. Portaro will assume the responsibilities of Chad A. Zaring, who is resigning from his role of Chief Commercial Officer for personal reasons, effective October 15, 2021. Mr. Zaring will continue to support the Company as a consultant through March 31, 2022. "Ross is an accomplished leader and industry veteran with more than 30 years of experience in the healthcare sector, including positions at Candela Med

      10/12/21 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    SEC Filings

    See more
    • Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Venus Concept Inc. (0001409269) (Filer)

      6/6/25 5:07:51 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - Venus Concept Inc. (0001409269) (Filer)

      6/2/25 4:28:55 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • SEC Form SD filed by Venus Concept Inc.

      SD - Venus Concept Inc. (0001409269) (Filer)

      5/30/25 7:00:18 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/8/24 7:51:38 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Venus Concept Inc.

      SC 13D/A - Venus Concept Inc. (0001409269) (Subject)

      10/3/24 7:59:41 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Venus Concept Inc.

      SC 13G/A - Venus Concept Inc. (0001409269) (Subject)

      9/30/24 9:53:26 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care

    $VERO
    Financials

    Live finance-specific insights

    See more
    • Venus Concept to Release First Quarter of Fiscal Year 2025 Financial Results on May 15, 2025

      TORONTO, April 07, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that first quarter of fiscal year 2025 financial results will be released before the market opens on Thursday, May 15, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on May 15, 2025 to discuss the results of the quarter and host a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13753054. A live webcast of the call will also be provided on the investor relations section of the Company's websi

      4/7/25 7:30:00 AM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Fourth Quarter and Fiscal Year 2024 Financial Results on March 31, 2025

      TORONTO, March 03, 2025 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that fourth quarter and fiscal year 2024 financial results will be released before the market opens on Monday, March 31, 2025. Management will host a conference call at 8:00 a.m. Eastern Time on March 31, 2025 to discuss the results of the quarter and the year with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13751985. A live webcast of the call will also be provided on the investor relations section of the

      3/3/25 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care
    • Venus Concept to Release Third Quarter of Fiscal Year 2024 Financial Results on November 13, 2024

      TORONTO, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Venus Concept Inc. ("Venus Concept" or the "Company") (NASDAQ:VERO), a global medical aesthetic technology leader, announced today that third quarter of fiscal year 2024 financial results will be released before the market opens on Wednesday, November 13, 2024. Management will host a conference call at 8:00 a.m. Eastern Time on November 13, 2024 to discuss the results of the quarter with a question and answer session. Those who would like to participate may dial 877-407-2991 (201-389-0925 for international callers) and provide access code 13749236. A live webcast of the call will also be provided on the investor relations section of the Company's

      10/2/24 4:05:00 PM ET
      $VERO
      Medical/Dental Instruments
      Health Care